Literature DB >> 11454863

Inhibition of p53 transcriptional activity by the S100B calcium-binding protein.

J Lin1, M Blake, C Tang, D Zimmer, R R Rustandi, D J Weber, F Carrier.   

Abstract

The levels of S100 Ca(2+)-binding proteins correlate with the progression of certain tumors, but their role, if any, in carcinogenesis is still poorly understood. S100B protein associates with both the p53 oligomerization domain (residues 325-355) and the extreme C terminus of the tumor suppressor p53 (residues 367-392). Consequently, S100B inhibits p53 tetramer formation and p53 phosphorylation mediated by protein kinase C, on p53 C-terminal end. In this report, we show that the S100B protein decreases p53 DNA binding and transcriptional activity. The effect of S100B is reflected in vivo by a reduced accumulation of p53, p21, and MDM2 protein levels in co-transfection assays and in response to bleomycin. The S100B can still interact with p53 in the absence of p53 extreme C-terminal end and reduce the expression of p53 downstream effector genes. These data indicate that S100B does not require p53 extreme C-terminal end to inhibit p53 activity. Collectively, these findings imply that elevated levels of S100B in tumors such as astrocytomas and gliomas could inhibit p53 functions and contribute to cancer progression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454863     DOI: 10.1074/jbc.M104379200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Protein S100A4: too long overlooked by pathologists?

Authors:  Luca Mazzucchelli
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

2.  The calcium-dependent interaction between S100B and the mitochondrial AAA ATPase ATAD3A and the role of this complex in the cytoplasmic processing of ATAD3A.

Authors:  Benoît Gilquin; Brian R Cannon; Arnaud Hubstenberger; Boualem Moulouel; Elin Falk; Nicolas Merle; Nicole Assard; Sylvie Kieffer; Denis Rousseau; Paul T Wilder; David J Weber; Jacques Baudier
Journal:  Mol Cell Biol       Date:  2010-03-29       Impact factor: 4.272

3.  S100B protein as a possible participant in the brain metastasis of NSCLC.

Authors:  Xiaowen Pang; Jie Min; Lili Liu; Yi Liu; Ningqiang Ma; Helong Zhang
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

4.  Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor.

Authors:  Maria Rosario Fernandez-Fernandez; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

5.  Theoretical study on binding of S100B protein.

Authors:  Artur Gieldon; Mattia Mori; Rebecca Del Conte
Journal:  J Mol Model       Date:  2007-08-23       Impact factor: 1.810

6.  Nucleophosmin sets a threshold for p53 response to UV radiation.

Authors:  Dony A Maiguel; Leslie Jones; Devulapalli Chakravarty; Chonglin Yang; France Carrier
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

Review 7.  The evolution of S100B inhibitors for the treatment of malignant melanoma.

Authors:  Kira G Hartman; Laura E McKnight; Melissa A Liriano; David J Weber
Journal:  Future Med Chem       Date:  2013-01       Impact factor: 3.808

8.  Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers.

Authors:  Jan van Dieck; Maria R Fernandez-Fernandez; Dmitry B Veprintsev; Alan R Fersht
Journal:  J Biol Chem       Date:  2009-03-18       Impact factor: 5.157

9.  S100B protein in tissue development, repair and regeneration.

Authors:  Guglielmo Sorci; Francesca Riuzzi; Cataldo Arcuri; Claudia Tubaro; Roberta Bianchi; Ileana Giambanco; Rosario Donato
Journal:  World J Biol Chem       Date:  2013-02-26

10.  The effect of pentamidine on melanoma ex vivo.

Authors:  Jason Smith; Benjamin J Stewart; Sharon Glaysher; Katharine Peregrin; Louise A Knight; David J Weber; Ian A Cree
Journal:  Anticancer Drugs       Date:  2010-02       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.